This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DEF
Quest Diagnostics (DGX) Expands COVID-19 Test Eligibility
by Zacks Equity Research
This zero out-of-pocket option applies to Quest Diagnostics' (DGX) molecular laboratory (PCR/NAAT) as well as rapid antigen testing.
QIAGEN (QGEN) Digital COVID-19 Antibody Test Gets FDA's EUA
by Zacks Equity Research
QIAGEN's (QGEN) QIAreach Anti-SARS-CoV-2 test takes nearly 10 minutes to detect whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More
by Urmimala Biswas
The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Quest Diagnostics (DGX) Q1 Earnings Miss, Base Recovery Strong
by Zacks Equity Research
The updated first-half 2021 outlook by Quest Diagnostics (DGX) looks impressive given its raised revenue and operating cash flow expectations.
Quest Diagnostics (DGX) Q1 Earnings Lag Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of -0.27% and 1.29%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Molecular Tests to Drive Quest Diagnostics (DGX) Q1 Earnings
by Zacks Equity Research
Through the first quarter, Quest Diagnostics' (DGX) several significant strides in the field of COVID-19 diagnostic testing are expected to have contributed to the top line.
Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DEF
Quest Diagnostics (DGX) Rides on Test Sales Amid Volume Woe
by Zacks Equity Research
Quest Diagnostics (DGX) enters into an agreement with the CDC to provide genomic sequencing to identify new mutations in and patterns of transmission of SARS-CoV-2.
Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions
by Zacks Equity Research
Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.
IQVIA (IQV) Buys Remaining Q2 Solutions Stake, Ups EPS View
by Zacks Equity Research
The latest deal is expected to help IQVIA (IQV) strengthen its Research & Development Solutions segment.
COVID-19 Resurgence Accelerates Diagnostic Testing: 3 Top Picks
by Urmimala Biswas
We have narrowed down our search to the following stocks, FLGT, BIO and IDXX based on a favorable Zacks Rank and strong prospects for 2021.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to strong demand for COVID-19 testing and well-positioned growth strategy.
Thermo Fisher (TMO) Launches Surveillance Tool for COVID-19
by Zacks Equity Research
The latest launch of surveillance solution is an extremely timely development by Thermo Fisher (TMO) and is expected to witness fast market adoption.
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy
by Urmimala Biswas
MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.
Quest Diagnostics (DGX) Inks Agreement to Enhance Cardiac Care
by Zacks Equity Research
Quest Diagnostics (DGX) signs agreement with Zora to develop cardiovascular mortality prediction test with the help of the latter's patented ceramide-analysis technology.
Quest Diagnostics (DGX) Q4 Earnings Top, Base Recovery Slows
by Zacks Equity Research
Quest Diagnostics' (DGX) first-half 2021 outlook looks impressive thanks to strong revenue growth expectations.
Quest Diagnostics (DGX) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.67% and 2.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Meridian Bioscience's (VIVO) Q1 Earnings?
by Zacks Equity Research
Meridian Bioscience's (VIVO) fiscal first-quarter results are likely to reflect strong performance by Life Science business line.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
Quest Diagnostics (DGX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quest Diagnostics (DGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Higher Testing to Aid Quest Diagnostics' (DGX) Q4 Earnings
by Zacks Equity Research
Within non-COVID base business, Quest Diagnostics (DGX) is expected to have secured higher returns in Q4 from the acquisitions of MACL, Memorial Hermann Outreach and Blueprint Genetics.